ETF Foundry
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.
momentum factor · long-only model fund

Foundry Healthcare 6-Month Momentum Factor ETF

ETF Foundry Research (hypothetical) · rebalanced monthly

FMOHHYPOTHETICAL MODEL
Since ’99
+196%
Expense Ratio
0.45%
placeholder
Holdings
97
cap-weighted
Inception
Jul 2022
placeholder
Full Sharpe
0.28
Ann. Return (LS)
8.2%
Ann. Volatility
29.4%
Max Drawdown
-75.9%
Test Sharpe ’19–26
0.50
Test FF5 α (ann.)
14.3%
vs Fama-French 5
Test FF5 α t-stat
1.63
not significant
Monthly turnover
33%
of the long leg, per rebalance
Cumulative return (LS)
196%
over 331 months
This fund holds the long leg only
Long leg Sharpe
0.63
what this fund holds
Long leg ann. return
16.8%
buyable, long-only
Long-short Sharpe
0.28
requires shorting
Bottom bucket ann. return
8.6%
the basket shorted

Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.

Hypothetical growth of $1 — long-short backtest

Gross of the placeholder expense ratio and trading costs · not investor results

331 months

Holdings

Every constituent of the long leg — sort, search or filter by sector

97 of 97 · 100.0% of book
TickerCompanySectorMarket capWeight
1HUM
HUMANA INCHealthcare$48.02B
11.44%
2RVMD
REVOLUTION MEDICINES INCHealthcare$39.58B
9.42%
3CNC
CENTENE CORPHealthcare$32.81B
7.81%
4ROIV
ROIVANT SCIENCES LTDHealthcare$24.82B
5.91%
5MRNA
MODERNA INCHealthcare$24.53B
5.84%
6DVA
DAVITA INCHealthcare$15.21B
3.62%
7BTSG
BRIGHTSPRING HEALTH SERVICES INCHealthcare$13.71B
3.26%
8APGE
APOGEE THERAPEUTICS INCHealthcare$10.10B
2.41%
9CORT
CORCEPT THERAPEUTICS INCHealthcare$9.72B
2.31%
10ALKS
ALKERMES PLCHealthcare$8.79B
2.09%
11OSCR
OSCAR HEALTH INCHealthcare$8.77B
2.09%
12SYRE
SPYRE THERAPEUTICS INCHealthcare$8.70B
2.07%
13TGTX
TG THERAPEUTICS INCHealthcare$8.40B
2.00%
14IBRX
IMMUNITYBIO INCHealthcare$8.04B
1.92%
15LQDA
LIQUIDIA CORPHealthcare$7.11B
1.69%
16LNTH
LANTHEUS HOLDINGS INCHealthcare$7.00B
1.67%
17HNGE
HINGE HEALTH INCHealthcare$6.74B
1.60%
18CGON
CG ONCOLOGY INCHealthcare$6.34B
1.51%
19LGND
LIGAND PHARMACEUTICALS INCHealthcare$6.08B
1.45%
20ERAS
ERASCA INCHealthcare$5.96B
1.42%
21TWST
TWIST BIOSCIENCE CORPHealthcare$5.84B
1.39%
22DNTH
DIANTHUS THERAPEUTICS INCHealthcare$5.77B
1.37%
23ORKA
ORUKA THERAPEUTICS INCHealthcare$5.59B
1.33%
24TXG
10X GENOMICS INCHealthcare$5.55B
1.32%
25DFTX
DEFINIUM THERAPEUTICS INCHealthcare$4.83B
1.15%
26EWTX
EDGEWISE THERAPEUTICS INCHealthcare$4.28B
1.02%
27TNGX
TANGO THERAPEUTICS INCHealthcare$4.13B
0.98%
28RLAY
RELAY THERAPEUTICS INCHealthcare$3.81B
0.91%
29DNLI
DENALI THERAPEUTICS INCHealthcare$3.70B
0.88%
30ALMS
ALUMIS INCHealthcare$3.65B
0.87%
31OGN
ORGANON & COHealthcare$3.55B
0.85%
32ELVN
ENLIVEN THERAPEUTICS INCHealthcare$3.24B
0.77%
33ACHC
ACADIA HEALTHCARE COMPANY INCHealthcare$3.17B
0.76%
34MBX
MBX BIOSCIENCES INCHealthcare$2.99B
0.71%
35QURE
UNIQURE NVHealthcare$2.54B
0.60%
36ASTH
ASTRANA HEALTH INCHealthcare$2.50B
0.60%
37SLS
SELLAS LIFE SCIENCES GROUP INCHealthcare$2.45B
0.58%
38NKTR
NEKTAR THERAPEUTICSHealthcare$2.31B
0.55%
39AGL
AGILON HEALTH INCHealthcare$2.17B
0.52%
40PLSE
PULSE BIOSCIENCES INCHealthcare$1.98B
0.47%
41ABCL
ABCELLERA BIOLOGICS INCHealthcare$1.97B
0.47%
42URGN
UROGEN PHARMA LTDHealthcare$1.96B
0.47%
43MRVI
MARAVAI LIFESCIENCES HOLDINGS INCHealthcare$1.87B
0.45%
44BCAX
BICARA THERAPEUTICS INCHealthcare$1.82B
0.43%
45BFLY
BUTTERFLY NETWORK INCHealthcare$1.73B
0.41%
46MPLT
MAPLIGHT THERAPEUTICS INCHealthcare$1.72B
0.41%
47ANAB
ANAPTYSBIO INCHealthcare$1.69B
0.40%
48CMPS
COMPASS PATHWAYS PLCHealthcare$1.67B
0.40%
49PSNL
PERSONALIS INCHealthcare$1.61B
0.38%
50VIR
VIR BIOTECHNOLOGY INCHealthcare$1.59B
0.38%
51NTLA
INTELLIA THERAPEUTICS INCHealthcare$1.59B
0.38%
52INNV
INNOVAGE HOLDING CORPHealthcare$1.56B
0.37%
53AVBP
ARRIVENT BIOPHARMA INCHealthcare$1.55B
0.37%
54AMN
AMN HEALTHCARE SERVICES INCHealthcare$1.36B
0.32%
55ABSI
ABSCI CORPHealthcare$1.29B
0.31%
56CRVS
CORVUS PHARMACEUTICALS INCHealthcare$1.25B
0.30%
57DRTS
ALPHA TAU MEDICAL LTDHealthcare$1.19B
0.28%
58AVNS
AVANOS MEDICAL INCHealthcare$1.17B
0.28%
59ETON
ETON PHARMACEUTICALS INCHealthcare$1.16B
0.28%
60MGTX
MEIRAGTX HOLDINGS PLCHealthcare$1.15B
0.27%
61CGEM
CULLINAN THERAPEUTICS INCHealthcare$1.09B
0.26%
62BIOA
BIOAGE LABS INCHealthcare$1.01B
0.24%
63SLDB
SOLID BIOSCIENCES INCHealthcare$859M
0.20%
64AVR
ANTERIS TECHNOLOGIES GLOBAL CORPHealthcare$823M
0.20%
65ACRS
ACLARIS THERAPEUTICS INCHealthcare$793M
0.19%
66ZVRA
ZEVRA THERAPEUTICS INCHealthcare$755M
0.18%
67CADL
CANDEL THERAPEUTICS INCHealthcare$746M
0.18%
68CLYM
CLIMB BIO INCHealthcare$727M
0.17%
69TECX
TECTONIC THERAPEUTIC INCHealthcare$615M
0.15%
70STTK
SHATTUCK LABS INCHealthcare$577M
0.14%
71FDMT
4D MOLECULAR THERAPEUTICS INCHealthcare$575M
0.14%
72IMMX
IMMIX BIOPHARMA INCHealthcare$558M
0.13%
73NVCT
NUVECTIS PHARMA INCHealthcare$508M
0.12%
74XOMA
XOMA ROYALTY CORPHealthcare$504M
0.12%
75CCRN
CROSS COUNTRY HEALTHCARE INCHealthcare$428M
0.10%
76STRO
SUTRO BIOPHARMA INCHealthcare$391M
0.09%
77ZNTL
ZENTALIS PHARMACEUTICALS INCHealthcare$364M
0.09%
78MASS
908 DEVICES INCHealthcare$278M
0.07%
79TTRX
TURN THERAPEUTICS INCHealthcare$272M
0.06%
80QTTB
Q32 BIO INCHealthcare$255M
0.06%
81ARTV
ARTIVA BIOTHERAPEUTICS INCHealthcare$241M
0.06%
82IMUX
IMMUNIC INCHealthcare$207M
0.05%
83BDSX
BIODESIX INCHealthcare$204M
0.05%
84FOCL
FOCAL INCHealthcare$204M
0.05%
85DTIL
PRECISION BIOSCIENCES INCHealthcare$203M
0.05%
86AMWL
AMERICAN WELL CORPHealthcare$199M
0.05%
87KRRO
KORRO BIO INCHealthcare$177M
0.04%
88PMN
PROMIS NEUROSCIENCES INCHealthcare$136M
0.03%
89CUE
CUE BIOPHARMA INCHealthcare$126M
0.03%
90CPIX
CUMBERLAND PHARMACEUTICALS INCHealthcare$103M
0.02%
91ICCC
IMMUCELL CORPHealthcare$101M
0.02%
92LIXT
LIXTE BIOTECHNOLOGY HOLDINGS INCHealthcare$91M
0.02%
93RLYB
RALLYBIO CORPHealthcare$87M
0.02%
94NRXS
NEURAXIS INCHealthcare$84M
0.02%
95PIII
P3 HEALTH PARTNERS INCHealthcare$78M
0.02%
96NMAD
NOMAD POWER SOLUTIONS INCHealthcare$72M
0.02%
97EDSA
EDESA BIOTECH INCHealthcare$59M
0.01%

Full long-leg book as of July 2026 · cap-weighted · total market cap $419.92B. Hypothetical model holdings — not a registered fund’s portfolio.

Sector Breakdown

1 sectors
Healthcare
100.0%

Portfolio Style

Size × value map of the long-leg book

97 classified
Value
Blend
Growth
Large
Mid
Small
20%5
31%11
29%13
5%12
4%9
3%6
2%21
<1%6
<1%5

Share of long-leg capital by market cap × book-to-market, using terciles of the 499-name universe at July 2026. Rows: Large ≥ $3.6B, Small < $964M. Columns: Value ≥ 0.67, Growth < 0.37 B/M. The dot marks the capital-weighted centroid of the book — 91% toward Large, 53% toward Growth. +4% unclassified (9 missing size/value). Hypothetical holdings — descriptive, not realized P&L.

Tilt over time
Size tilt91% → Large
SmallLarge
Value ↔ growth tilt53% → Growth
ValueGrowth

Capital-weighted centroid of the long leg, December 1998July 2026; the right-hand end is the same value as the box’s dot. 97 names now. Hypothetical holdings — descriptive, not P&L.

Constraint checks

How this book measures against the concentration and liquidity rules — as implemented here

How this book was built

These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.

Passed
6
Failed
0
Not tested
1
Independent checks
7

7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.

1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.

Reported separately — arithmetically implied

Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.

No verdict sits within 1.0pp of its limit.

Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700

Measured on the 2026-07 formation date across 97 holdings (cap-weighted). A different formation date can produce different verdicts.

Derivatives risk (Rule 18f-4)

Whether this long-only book is subject to the VaR tests at all

This assessment describes the long-only book this fund holds — the top bucket only.

Governing rule
Rule 18f-4(c)(4) limited derivatives user exception

This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.

Limited derivatives user exceptionby construction

Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.

Qualifies
Required
<= 10% of net assets
Exposure
0% of net assets
Margin
+10pp

No confidence interval: this follows from portfolio construction, not from an estimate.

Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.

Informational — does not govern

This fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.

Measured
1.7 (95% CI 1.1-2.1)
x reference VaR
Limit
2.00x
<= 2.00x reference VaR
Fund VaR
16.6%
99% / 20d
Reference
9.6%
FF5 market (mkt)

historical method · 331 monthly observations · about 3.3 in the 99% tail · paired percentile bootstrap over months

Same test, three estimators
historical
1.73x
within
parametric
1.69x
within
cornish fisher
2.32x
over · unreliable

The estimators agree, which is mild evidence the number isn’t an artefact of one method.

Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.

The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.

See the long-short verdict on the factor page →

Since publication

Did the edge survive the paper coming out?

published 1993
Entirely since publication
All 331 months of our record post-date the 1993 paper.
Sharpe 0.288.2% p.a.January 1999July 2026

There is no “before” to compare against — the predictor was already public when our data begins, so every month shown is out-of-sample relative to the original study.

Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.

Consistency across eras

Is this record broadly durable, or one regime?

26 windows
Positive windows
54%
14 of 26 3-year windows made money
Worst window
-0.53
Sharpe, January 2008 – December 2010
January 1999July 2026
Median Sharpe
0.05
Dispersion
0.53
Best window
1.69

3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.

Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.

Returns

Long leg is what this fund holds — long-short is shown for reference

since January 1999
Trailing
PeriodLong legLong-short
1 yearcum.55.5%13.9%
3 yearsp.a.20.3%12.6%
5 yearsp.a.13.2%16.3%
10 yearsp.a.18.8%14.6%
Since inceptionp.a.14.2%4.0%
Calendar years
YearLong legLong-short
20267 mo17.8%24.8%
202539.0%23.0%
202410.4%4.6%
2023-2.9%-28.9%
2022-4.3%31.8%
202137.2%92.9%
202051.0%16.3%
20199.6%-40.8%
20182.5%25.6%
201750.3%44.5%
2016-14.7%13.1%
20154.6%-13.3%
201413.6%-15.7%
201362.0%23.1%
201214.8%-9.5%
201117.4%30.2%
201011.5%-12.4%
200927.1%-24.7%
2008-17.3%1.2%
20077.5%-1.0%
2006-2.0%-15.8%
200530.1%14.2%
2004-1.9%-15.1%
200341.3%13.3%
2002-34.6%-27.6%
2001-10.2%-7.9%
200038.5%9.2%
199965.6%52.6%

Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.

Fund Facts

Ticker (pseudo)FMOH
IssuerETF Foundry Research (hypothetical)
SeriesHypothetical Model Portfolio Series (not a registered trust)
Expense ratio0.45% (placeholder)
Inception2022-07-21 (placeholder)
Listing exchangeNot listed (hypothetical)
CUSIPNot applicable (hypothetical model portfolio)
RebalanceMonthly
Holdings as ofJuly 2026
Total mkt cap (long leg)$419.92B

Methodology

The Foundry Healthcare 6-Month Momentum Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a 6-Month Momentum signal and holds the top quintile with the highest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.

This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.

Documents (draft — hypothetical)

Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.

Summary Prospectus

Objective, fees, strategy, and key risks.

View →
Prospectus

Full strategy, model methodology, and risks.

View →
Statement of Additional Information

Policies, construction, and governance.

View →
Fact Sheet

One-page snapshot with top holdings.

View →
Daily Holdings

Full current constituent list.

View →

DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.